Express Pharma

China approves its first mRNA vaccine from CSPC

The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed good neutralisation effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5 and CH.1.1. in clinical trials

0 339